These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33641556)

  • 1. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
    Fukuda M; Naito Y
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Haratake N; Seto T
    Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 7. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
    Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y
    Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTRK fusions in colorectal cancer: clinical meaning and future perspective.
    Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC
    Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS; Lassen U
    Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
    Hong DS; Drilon A; Wirth LJ
    Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
    Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diagnosis and therapy of tumors with NTRK gene fusion].
    Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
    Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
    Forschner A; Forchhammer S; Bonzheim I
    J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK fusions in osteosarcoma are rare and non-functional events.
    Ameline B; Saba KH; Kovac M; Magnusson L; Witt O; Bielack S; Nathrath M; Nord KH; Baumhoer D
    J Pathol Clin Res; 2020 Apr; 6(2):107-112. PubMed ID: 32022484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.